Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the SARS-CoV-2 coronavirus. Otezla ...
Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on getting a longer period of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback